NCT02117713已完成2 期
A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 11
- 主要终点
- Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)
研究概览
简要总结
This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome who have completed participation in a core LUM001 treatment protocol. The primary objective is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with Alagille Syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 1 Year 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 12 months to 18 years of age.
- •Competent to provide informed consent and assent (per institutional review board/Ethics Committee [IRB/EC]), as appropriate.
- •Completed participation in the LUM001-301 protocol.
- •Females of childbearing potential must have a negative urine pregnancy test [beta human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.
- •Sexually active females must be prepared to use an effective method of contraception during the trial.
- •Effective methods of contraception are considered to be:
- •Hormonal (for example, contraceptive pill, patch, intramuscular implant or injection); or
- •Barrier method, for example, (a) condom with spermicide, or (b) diaphragm, with spermicide; or
- •Intrauterine device (IUD).
- •Participants above the age of assent and caregivers and children must be able to read and understand English or Spanish.
- •Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
- •Caregivers (and age appropriate participants) must be willing and able to complete a daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 consecutive weeks following the Week 24 and Week 44 visits.
- •Caregivers (and age appropriate participants) must digitally accept the licensing agreement in the ItchRO electronic diary software at the outset of the study.
- •Eligible participants must be able to adhere to local Ethics Committee or Institutional Review Board (IRB) blood volume limits for laboratory testing.
- •The participant has completed the protocol either through Week 144, or the End of Trial visit, or has received permission from the sponsor and the Premier Medical monitor to re-enter the study in the long-term, optional follow-up treatment period
- •Females of child-bearing potential must have a negative urine or serum pregnancy test (beta-HCG]) at the time of entry into the long-term optional follow-up treatment period
- •Male and female participants of child-bearing potential who are sexually active, or are not currently sexually active, but become sexually active during the study or for 30 days following the last dose of study drug, must agree to use acceptable contraception during the study.
- •Informed consent and assent (per IRB/EC) as appropriate.
- •Caregivers (and age appropriate participants) must have access to phone for scheduled calls from study site.
- •Caregivers (and age appropriate participants) must be willing to follow the rules of eDiary completion.
排除标准
- •Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001-301 protocol that led to the discontinuation of the participant from the core study.
- •Any conditions or abnormalities (including laboratory abnormalities) which in the opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
- •History or known presence of gallstones or kidney stones.
- •History of non-adherence during the participant's participation in the LUM001-301 protocol. Non-adherence is defined by dosing compliance (dosing compliance is calculated by [the total number of doses that were actually taken by the participant] divided by [the total number of doses that should have been taken by the participant] multiplied by 100) of less than 80% in the LUM001-301 protocol.
- •Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by the investigator.
- •All above exclusion criteria will apply upon re-entry into the long-term, optional follow-up treatment period 2.
研究组 & 干预措施
LUM001 (Maralixibat)
Experimental
Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
干预措施: LUM001 (Maralixibat) (Drug)
结局指标
主要结局
Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)
时间窗: Baseline to Week 48
This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.
次要结局
- Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)(Baseline to week 216)
- Change From Baseline to Week 218 in Pruritus(Baseline to Week 218)
- Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score(Baseline to Week 216)
- Change From Baseline to Week 216 in Alanine Aminotransferase(Baseline to week 216)
- Change From Baseline to End of Treatment in Alkaline Phosphatase(Baseline to Week 216)
- Change From MRX Baseline to Week 216 in Aspartate Aminotransferase(Baseline to week 216)
- Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score(Baseline to week 216)
- Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase(Baseline to Week 216)
- Mean Change From MRX Baseline to Week 216 in Total Bilirubin(Baseline to week 216)
- Mean Change From MRX Baseline to Week 216 in Direct Bilirubin(Baseline to week 216)
研究者
研究点 (11)
Loading locations...
相似试验
终止
2 期
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseAlzheimer's DiseaseNCT05744401Alector Inc.197
已完成
2 期
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary HyperparathyroidismHyperparathyroidism, PrimaryNCT00936988Amgen45
终止
3 期
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European CountriesDyslipidemiaNCT03080935Amgen1,600
已完成
3 期
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher DiseaseGaucher DiseaseNCT01422187Pfizer19
已完成
2 期
Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) StudiesPompe Disease Infantile-OnsetGlycogen Storage Disease Type IINCT00763932Genzyme, a Sanofi Company7